<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00732420</url>
  </required_header>
  <id_info>
    <org_study_id>HYT109091</org_study_id>
    <nct_id>NCT00732420</nct_id>
  </id_info>
  <brief_title>Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Two Schedules of Oral Topotecan in Combination With Pazopanib in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determined what dose of topotecan can be safely given with daily pazopanib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Two Schedules&#xD;
      of Oral Topotecan in combination with Pazopanib in Subjects with Advanced Solid Tumors&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2008</start_date>
  <completion_date type="Actual">June 12, 2013</completion_date>
  <primary_completion_date type="Actual">June 12, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First course tolerability with rising dose of topotecan to determine the maximum tolerated dose of topotecan when given with pazopanib daily.</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Indications of efficacy through tumour shrinkage. Specific biomarker analysis.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Solid Tumours</condition>
  <arm_group>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral pazopanib in combination with weekly oral topotecan. Initially rising dose to determine the maximum tolerated dose: finally an expanded cohort treated at the maximum tolerated dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral pazopanib in combination with oral topotecan given for 5 consecutive days every 21 days. Initially rising dose to determine the maximum tolerated dose; finally an additional cohort of patients treated at the maximum tolerated dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan</intervention_name>
    <description>Topoisomerase I inhibition.</description>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_label>Treatment Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pazopanib</intervention_name>
    <description>Tyrosine kinase inhibitor</description>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_label>Treatment Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria -&#xD;
&#xD;
          -  signed, written informed consent.&#xD;
&#xD;
          -  at least 18 years of age.&#xD;
&#xD;
          -  ECOG performance status 0 or 1.&#xD;
&#xD;
          -  Subjects must have histologically or cytologically confirmed diagnosis of advanced&#xD;
             cancer and a solid tumor malignancy that has relapsed or is refractory to standard&#xD;
             therapy or for which there is no established therapy.&#xD;
&#xD;
          -  able to swallow and retain oral medications.&#xD;
&#xD;
          -  females are eligible to enter and participate in this study providing adequate&#xD;
             established contraception is being practiced.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin&#xD;
             C)&#xD;
&#xD;
          -  received an investigational drug within 30 days or 5 half-lives (whichever is longer).&#xD;
&#xD;
          -  received prior treatment with pazopanib/investigational anti-angiogenic compounds.&#xD;
&#xD;
          -  presence of uncontrolled infection.&#xD;
&#xD;
          -  pregnant or lactating.&#xD;
&#xD;
          -  poorly controlled hypertension (SBP of ? 140 mmHg, or DBP of ? 90 mmHg.&#xD;
&#xD;
          -  Class III or IV heart failure as defined by the New York Heart Association (NYHA)&#xD;
             functional classification system.-&#xD;
&#xD;
          -  arterial thrombi, myocardial infarction, admission for unstable angina, uncontrolled&#xD;
             or symptomatic arrhythmia, cardiac angioplasty, or stenting within the last 6 months.&#xD;
&#xD;
          -  any unresolved bowel obstruction or diarrhea ? Grade 1.&#xD;
&#xD;
          -  received an allogeneic bone marrow transplant.&#xD;
&#xD;
          -  known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             chemically related to pazopanib or topotecan.&#xD;
&#xD;
          -  any serious and/or unstable pre-existing medical, psychiatric, or other conditions&#xD;
             that could interfere with subject's safety, obtaining informed consent or compliance&#xD;
             with the study.&#xD;
&#xD;
          -  psychological, familial, sociological, or geographical conditions that do not permit&#xD;
             compliance with the protocol.&#xD;
&#xD;
          -  clinical history, current alcohol or illicit drug use which, in the judgment of the&#xD;
             investigator, would interfere with the subject's ability to comply with the dosing&#xD;
             schedule and protocol-specified evaluations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>August 11, 2008</study_first_submitted>
  <study_first_submitted_qc>August 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2008</study_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pazopanib</keyword>
  <keyword>Phase I</keyword>
  <keyword>topotecan</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

